| 臺大學術典藏 |
2021-05-03T02:20:41Z |
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
|
Andr? T.;Vernerey D.;Im S.A.;Bodoky G.;Buzzoni R.;Reingold S.;Rivera F.;Mckendrick J.;Scheithauer W.;Ravit G.;Fountzilas G.;Yong W.P.;Isaacs R.;?Sterlund P.;Jin-Tung Liang;Creemers G.J.;Rakez M.;Van Cutsem E.;Cunningham D.;Tabernero J.;De Gramont A.; Andr? T.; Vernerey D.; Im S.A.; Bodoky G.; Buzzoni R.; Reingold S.; Rivera F.; McKendrick J.; Scheithauer W.; Ravit G.; Fountzilas G.; Yong W.P.; Isaacs R.; ?sterlund P.; JIN-TUNG LIANG; Creemers G.J.; Rakez M.; Van Cutsem E.; Cunningham D.; Tabernero J.; de Gramont A. |
| 臺大學術典藏 |
2020-01-22T07:50:23Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Chiang Y.-C.; CHI-AN CHEN; Cheng W.-F.; Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chi-An Chen;Cheng W.-F.; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L. |
| 臺大學術典藏 |
2020-02-06T05:21:47Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG; WEN-FANG CHENG;Chen C.-A.;Chiang Y.-C.;Chen Y.-L.;Tai Y.-J.;Hsu H.-C.;Lee S.-P.; Lee S.-P. |
| 臺大學術典藏 |
2020-02-14T02:49:36Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chen C.-A.;Wen-Fang Cheng; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG |
| 臺大學術典藏 |
2020-02-14T08:50:30Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P; Hsu H.-C; Tai Y.-J; Chen Y.-L; YING-CHENG CHIANG; Chen C.-A; Cheng W.-F. |
| 臺大學術典藏 |
2020-05-24T06:00:15Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; Tai Y.-J.; YU-LI CHEN; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T02:39:51Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Yu-Li Chen;Chiang Y.-C.;Chen C.-A.;Cheng W.-F.; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; YU-LI CHEN; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T06:11:34Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; YI-JOU TAI; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T07:44:50Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; YING-CHENG CHIANG; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-09-27T06:18:43Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; HENG-CHENG HSU; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-03-10T02:34:33Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Heng-Cheng Hsu;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chen C.-A.;Cheng W.-F.; Lee S.-P.; HENG-CHENG HSU; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 國立臺灣大學 |
2009 |
Bevacizumab for the Treatment of Corneal Neovascularization
|
陳偉勵; 陳彥名; 朱筱桑; 蔡紫筠; 胡芳蓉; CHEN, WEI-LI; CHEN, YAN-MING; CHU, HSIAO-SANG; TSAI, TZU-YUN; HU, FUNG-RONG |
| 臺大學術典藏 |
2020-10-22T07:41:52Z |
Bevacizumab for the treatment of corneal neovascularization
|
Hu F.-R.; Lin Y.-H.; Tsai T.-Y.; Chu H.-S.; Chen Y.-M.; WEI-LI CHEN |
| 臺大學術典藏 |
2022-07-15T08:17:47Z |
Bevacizumab for the treatment of corneal neovascularization
|
Chen W.-L.; Chen Y.-M.; Chu H.-S.; Lin Y.-H.; Tsai T.-Y.; FUNG-RONG HU |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
|
Chih-Hsin Yang; CHIH-HSIN YANG |
| 國立臺灣大學 |
2009 |
Bevacizumab Is Not Toxic to Retinal Ganglion Cells after Repeated Intravitreal Injection
|
鄭成國; 彭百慧; 田履黛; 陳朝峰; 李憶菁; CHENG, CHENG-KUO; PENG, PAI-HUEI; TIEN, LU-TAI; CHEN, CHAU-FONG; LEE, YIH-JING |
| 國立臺灣大學 |
2016 |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen, I-Chun; Lin, Ching-Hung; Jan, I-Shiow; Cheng, Ann-Lii; Lu, Yen-Shen; 盧彥伸; 林璟宏; 詹一秀; 陳怡君; 鄭安理; 林季宏 |
| 臺大學術典藏 |
2018-09-10T09:41:56Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen;林季宏; Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen; Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen; 盧彥伸;林璟宏;詹一秀;陳怡君;鄭安理;林季宏; I-SHIOW JAN; Kao, Jia-Horng; Chen, I-Chun; Lin, Ching-Hung; CHING-HUNG LIN; Lin, Ching-Hung; ANN-LII CHENG; Jan, I-Shiow; Jan, I-Shiow; Cheng, Ann-Lii; Cheng, Ann-Lii; Lu, Yen-Shen; Lu, Yen-Shen; 高嘉宏 |
| 臺大學術典藏 |
2020-05-25T06:51:50Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C;Lin C.-H;Jan I.-S;Cheng A.-L;Yen-Shen Lu; Chen I.-C; Lin C.-H; Jan I.-S; Cheng A.-L; YEN-SHEN LU |
| 臺大學術典藏 |
2021-08-16T03:26:39Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
I-CHUN CHEN; Lin C.-H.; Jan I.-S.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C.; Lin C.-H.; Jan I.-S.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-03-12T00:50:54Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C.; Lin C.-H.; I-SHIOW JAN; Cheng A.-L.; Lu Y.-S. |
| 臺北醫學大學 |
2012 |
Bevacizumab plus Docetaxel and Cisplatin for Metastatic Breast Cancer: A Pilot Phase II Study
|
CJ, Tai;CS, Chen;CS, Hung;LJ, Kuo;PL, Wei;JF, Chiou;CH, Hsu;HY, Chiou;CH, Wu |
| 國立臺灣大學 |
2015 |
Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy
|
Lu, Yen-Shen; Chen, Tom Wei-Wu; Lin, Ching-Hung; Yeh, Dah-Cherng; Tseng, Ling-Ming; Wu, Pei-Fang; Rau, Kun-Ming; Chen, Bang-Bin; Chao, Ta-Chung; Huang, Shu-Min; Huang, Chiun-Sheng; Shih, Tiffany Ting-Fang; Cheng, Ann-Lii; 林志弘; 陳偉武; 盧彥伸; 林璟宏; 施庭芳; 吳佩芳; 鄭安理; 陳邦斌; 黃俊升; 林季宏 |
| 臺大學術典藏 |
2018-09-10T15:18:47Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Tseng, Ling-Ming; ANN-LII CHENG; Tseng, Ling-Ming; Wu, Pei-Fang; Wu, Pei-Fang; Rau, Kun-Ming; Chen, Bang-Bin; Chen, Bang-Bin; Chao, Ta-Chung; Chao, Ta-Chung; Huang, Shu-Min; Huang, Shu-Min; Huang, Chiun-Sheng; Huang, Chiun-Sheng; Shih, Tiffany Ting-Fang; Shih, Tiffany Ting-Fang; Cheng, Ann-Lii; Yeh, Dah-Cherng; CHING-HUNG LIN; Yeh, Dah-Cherng; Lin, Ching-Hung; Lin, Ching-Hung; BANG-BIN CHEN; Chen, Tom Wei-Wu; 林志弘;陳偉武;盧彥伸;林璟宏;施庭芳;吳佩芳;鄭安理;陳邦斌;黃俊升;林季宏; Lu, Yen-Shen;Chen, Tom Wei-Wu;Lin, Ching-Hung;Yeh, Dah-Cherng;Tseng, Ling-Ming;Wu, Pei-Fang;Rau, Kun-Ming;Chen, Bang-Bin;Chao, Ta-Chung;Huang, Shu-Min;Huang, Chiun-Sheng;Shih, Tiffany Ting-Fang;Cheng, Ann-Lii; TIFFANY TING-FANG SHIH; Lu, Yen-Shen; Lu, Yen-Shen; Chen, Tom Wei-Wu; CHIUN-SHENG HUANG |
| 臺大學術典藏 |
2015 |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Cheng A.-L.; Shih T.T.-F.; CHIUN-SHENG HUANG; Huang S.-M.; Chao T.-C.; Chen B.-B.; Rau K.-M.; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2020-05-25T06:51:53Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Shih T.T.-F; Cheng A.-L; Taiwan Breast Cancer Consortium; Huang C.-S; Huang S.-M; Chao T.-C; Chen B.-B; Rau K.-M; Wu P.-F; Tseng L.-M; Yeh D.-C; Lin C.-H; Chen T.W.-W; YEN-SHEN LU; Taiwan Breast Cancer Consortium;Cheng A.-L;Shih T.T.-F;Huang C.-S;Huang S.-M;Chao T.-C;Chen B.-B;Rau K.-M;Wu P.-F;Tseng L.-M;Yeh D.-C;Lin C.-H;Chen T.W.-W;Yen-Shen Lu |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.;Chen T.W.-W.;Lin C.-H.;Yeh D.-C.;Tseng L.-M.;Wu P.-F.;Rau K.-M.;Chen B.-B.;Chao T.-C.;Huang S.-M.;Huang C.-S.;Tiffany Ting-Fang Shih;Cheng A.-L.;Taiwan Breast Cancer Consortium; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; TIFFANY TING-FANG SHIH; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2022-03-15T05:39:30Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-03-18T03:23:37Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; ANN-LII CHENG; Taiwan Breast Cancer Consortium |
| 國立臺灣大學 |
2008 |
Bevacizumab Pretreatment and Long-Acting Gas Infusion on Vitreous Clear- up after Diabetic Vitrectomy
|
楊中美; 葉伯廷; 楊長豪; 陳慕師; YANG, CHUNG-MAY; YEH, PO-TING; YANG, CHANG-HAO; CHEN, MUH-SHY |
| 臺大學術典藏 |
2018-09-10T06:48:56Z |
Bevacizumab Pretreatment and Long-acting Gas Infusion on Vitreous Clear-up After Diabetic Vitrectomy
|
Yang, C.-M. and Yeh, P.-T. and Yang, C.-H. and Chen, M.-S.; 楊中美;葉伯廷;楊長豪;陳慕師; Yang, CM;Yeh, PT;Yang, CH;Chen, MS.; YANG, CHUNG-MAY;YEH, PO-TING;YANG, CHANG-HAO;CHEN, MUH-SHY; CHUNG-MAY YANG; Yang, CM; Yeh, PT; CHANG-HAO YANG; PO-TING YEH; Yang, CH; Chen, MS. |
| 臺大學術典藏 |
2022-07-15T06:43:33Z |
Bevacizumab Pretreatment and Long-acting Gas Infusion on Vitreous Clear-up After Diabetic Vitrectomy
|
CHUNG-MAY YANG; Yeh P.-T.; Yang C.-H.; Chen M.-S. |
| 臺大學術典藏 |
2022-07-20T06:34:01Z |
Bevacizumab Pretreatment and Long-acting Gas Infusion on Vitreous Clear-up After Diabetic Vitrectomy
|
Yang C.-M.; PO-TING YEH; Yang C.-H.; Chen M.-S. |
| 國立臺灣大學 |
2008-06 |
Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy.
|
Yang, CM; Yeh, PT; Yang, CH; Chen, MS. |
| 國立臺灣大學 |
2009 |
Bevacizumab Pretreatment in Vitrectomy with Silicone Oil for Severe Diabetic Retinopathy
|
葉伯廷; 楊中美; 林友祺; 陳慕師; 楊長豪; YEH, PO-TING; YANG, CHUNG-MAY; LIN, YU-CHI; CHEN, MUH-SHY; YANG, CHANG-HAO |
| 臺大學術典藏 |
2022-07-14T07:25:57Z |
Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy
|
Yeh P.-T.; Yang C.-M.; Lin Y.-C.; Chen M.-S.; CHANG-HAO YANG |
| 臺大學術典藏 |
2022-07-15T06:43:28Z |
Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy
|
Yeh P.-T.; CHUNG-MAY YANG; Lin Y.-C.; Chen M.-S.; Yang C.-H. |
| 臺大學術典藏 |
2022-07-20T06:34:01Z |
Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy
|
PO-TING YEH; Yang C.-M.; Lin Y.-C.; Chen M.-S.; Yang C.-H. |
| 臺北醫學大學 |
2018-07 |
Bevacizumab Reduces S100A9+ MDSC Linked to Intracranial Control in Patients with EGFR Mutant Lung Adenocarcinoma.
|
馮博皓; Po-Hao Feng, Kuan-Yuan Chen, Yu-Chen Huang, Ching-Shan Luo, Shen Ming Wu, Tzu-Tao Chen, Chun-Nin Lee, Chi-Tai Yeh, Hsiao-Chi Chuang, Chia-Li Han, Chiou-Feng Lin, Wei-Hwa Lee, Chih-Hsi Kuo, Kang-Yun Lee |
| 臺大學術典藏 |
2013 |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU; Cheng A.-L. |
| 國立成功大學 |
2013 |
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
|
Hsu, Chih-Hung; Kang, Yoon Koo; Yang, Tsai-Shen; Shun, Chia-Tung; Shao, Yu-Yun; Su, Wu-Chou; Sandoval-Tan, Jennifer; Chiou, Tzeon-Jye; Jin, Kate; Hsu, Chiun; Cheng, Ann-Lii |
| 國立臺灣大學 |
2013 |
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
|
Hsu, Chih-Hung; Kang, Yoon Koo; Yang, Tsai-Shen; Shun, Chia-Tung; Shao, Yu-Yun; Su, Wu-Chou; Sandoval-Tan, Jennifer; Chiou, Tzeon-Jye; Jin, Kate; Hsu, Chiun; Cheng, Ann-Lii; 邵幼雲; 鄭安理; 徐志宏; 許駿; 孫家棟 |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.; Cheng A.-L.; Jin K.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO; Su W.-C.; Sandoval-Tan J.; Chiou T.-J. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Chiun Hsu; Cheng A.-L.; Yang T.-S.; Shun C.-T.; Shao Y.-Y. |
| 臺大學術典藏 |
2021-03-18T02:02:48Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T01:53:47Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; ANN-LII CHENG |
| 高雄醫學大學 |
2009 |
Bevacizumab在缺血性視神經病變治療的應用 -- 初報
|
吳文權;賴昱宏 |
| 國立臺灣大學 |
2010 |
Bevacizumab結膜下腔注射在眼輪部幹細胞缺損模式中對於角膜新生血管與角膜結膜化的抑制效果
|
郭廣慈; Kuo, Kuang-Tzu |
